Clinical trial · Interventional
Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy
Iscar For Supplemental Care In Advanced Non-Small Cell Lung Carcinoma
NCT00052325CI-TRIAL-00013079unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Mistletoe may help the body build an immune response and may improve quality of life to help patients live more comfortably. PURPOSE: This phase II trial is studying mistletoe to see how well it works in treating patients who are receiving palliative chemotherapy for stage IIIB or stage IV non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mistletoe extract | Dietary Supplement | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Stage IIIB or IV non-small cell lung cancer * Newly diagnosed disease * Planning to receive standard chemotherapy with either carboplatin plus paclitaxel or cisplatin plus gemcitabine * Refused or ineligible to participate in experimental chemotherapy clinical trials PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 60-100% Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Other * Not pregnant * No AIDS * Able to self-report quality of life * No known allergy to Viscum album Linnaeus PRIOR CONCURRENT THERAPY: Biologic therapy * No other concurrent mistletoe products Chemotherapy * See Disease Characteristics Endocrine therapy * No concurrent steroid or adrenocorticotropic hormone therapy Radiotherapy * Not specified Surgery * Not specified Other * No concurrent participation in other clinical trials * No concurrent mushroom glucan or proteoglycan extracts * No concurrent thymus extract * No concurrent non-oncologic immunosuppressive therapy (e.g., therapy for rheumatoid arthritis or after organ transplantation)
References
Publications (0)
Data not yet available
No reference posted for this study.